Additional file 1 of Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

Additional file 1: Table S1. Concentrations of metabolites in the IPF and control cohorts; Table S2. Concentrations of clinical analytes in the IPF and control cohorts; Table S3. Differences in metabolite levels between IPF cases and controls; Table S4. Differences in clinical analyte levels between the IPF and control cohorts; Table S5. Differences in metabolite and clinical analyte levels between patients with IPF who were and were not using anti-fibrotic therapy at enrollment; Table S6. Associations of circulating metabolites with DLco % predicted at enrollment in patients with IPF, unadjusted and adjusted for use of anti-fibrotic therapy at enrollment; Table S7. Association of circulating metabolites with FVC % predicted at enrollment in patients with IPF, unadjusted and adjusted for use of anti-fibrotic therapy at enrollment; Table S8. Association of circulating metabolites with composite physiologic index at enrollment in patients with IPF unadjusted and adjusted for use of anti-fibrotic therapy at enrollment; Figure S1. Adjusted univariate associations between metabolites and risk of outcomes